Drugs / Rabies vaccine
Rabies vaccine
also known as
Verorab · Rabipur · RabAvert · Cell-culture rabies vaccine · PVRV · Abhayrab · ChengDa rabies vaccine · Inactivated rabies virus vaccine · +5 more
Trials 24 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07399951 | Oct 2023 → Jun 2025 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT04715867 | Jan 2021 → Dec 2022 | — | International Centre for Diarrhoeal Disease Research, Bangladesh | Unknown | No outcome recorded |
| Phase 1 | NCT04019444 | Sep 2019 → Mar 2023 | rabies | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02458092 | Apr → Dec 2008 | malaria | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 1 | NCT00424944 | Jun 2007 → Jul 2008 | malaria | African Malaria Network Trust | Unknown | No outcome recorded |
| Phase 1 | NCT00358332 | Nov 2006 → Dec 2007 | Plasmodium falciparum malaria | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02956746 | Aug 2016 → Dec 2017 | rabies | Synermore Biologics Co., Ltd. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07445815 | Jan → Jul 2026 overdue | — | Lanzhou Institute of Biological Products Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06799234 | Jul 2025 → Mar 2026 overdue | Rift valley fever | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03276962 | Sep 2017 → Nov 2019 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02276625 | Oct 2014 → Feb 2016 | rabies | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02040090 | Apr 2013 → Aug 2014 | rabies | Kamada, Ltd. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07455318 | May 2026 → Jun 2027 expected | — | Institute of Tropical Medicine, Belgium | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT02545517 | Oct 2015 → Dec 2022 | rabies | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01680016 | Sep 2012 → Jan 2013 | rabies | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT01107275 | Nov 2002 → Nov 2004 | rabies | Provincial Public Health Office, Phetchabun | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT05453487 | Jul → Oct 2022 | COVID-19, rabies | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT03192371 | Feb 2018 → May 2019 | viral infectious disease | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 4 | NCT02564471 | Nov 2016 → Aug 2018 | rabies | State University of New York - Upstate Medical University | Completed | No outcome recorded |
| Phase 4 | NCT02490956 | Apr 2015 → Sep 2016 | immunodeficiency disease | Chulalongkorn University | Unknown | No outcome recorded |
| Phase 4 | NCT02374814 | Mar 2015 → Sep 2016 | rabies | State University of New York - Upstate Medical University | Completed | No outcome recorded |
| Phase 4 | NCT01173302 | May → Aug 2010 | rabies | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT02547727 | Feb 2016 → Dec 2023 | rabies | Queen Saovabha Memorial Institute | Unknown | No outcome recorded |
| — | NCT01641315 | Sep 2015 → Apr 2018 | rabies | Queen Saovabha Memorial Institute | Completed | No outcome recorded |
Also used as a comparator or background therapy in 50 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT07124156 Comparator | Mar → Jul 2026 overdue | malaria | European Vaccine Initiative | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07342257 Background | Nov 2024 → May 2025 | rabies | Synermore Biologics (Suzhou) Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06048770 Comparator | Sep 2023 → Jul 2024 | — | Replicate Bioscience | Terminated | No outcome recorded |
| Phase 1 | NCT05644067 Comparator | Aug 2023 → Apr 2024 | malaria | Swiss Tropical & Public Health Institute | Completed | No outcome recorded |
| Phase 1 | NCT05135273 Comparator | Oct 2021 → Feb 2023 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT04062669 Comparator | Aug 2019 → Jul 2021 | viral infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT03713086 Comparator | Oct 2018 → Nov 2021 | rabies | CureVac | Completed | No outcome recorded |
| Phase 1 | NCT02657161 Comparator | Feb → Jul 2015 | rabies | Yisheng Biopharma (Singapore) Pte. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02238756 Comparator | Sep 2014 → Sep 2015 | rabies | CureVac | Completed | No outcome recorded |
| Phase 1 | NCT00703066 Comparator | Jun 2008 → Jul 2009 | malaria | African Malaria Network Trust | Unknown | No outcome recorded |
| Phase 1 | NCT00349713 Comparator | Nov 2004 → Dec 2005 | Plasmodium falciparum malaria | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04495569 Background | Feb → Jun 2019 | rabies | Synermore Biologics (Suzhou) Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT01635647 Comparator | Nov 2012 → Aug 2014 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 216 trials | ||||||
| Phase 2 | NCT07055880 Comparator | Jul 2025 → Jan 2026 overdue | rabies | Sinovac Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03961555 Background | Sep 2019 → Dec 2021 | rabies | Synermore Biologics Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02956421 Comparator | Feb → Oct 2016 | rabies | Yisheng Biopharma (Singapore) Pte. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01658696 Comparator | Aug 2012 → Feb 2013 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT01666925 Comparator | Mar → Aug 2012 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT01341704 Comparator | May → Dec 2011 | Plasmodium falciparum malaria | Vac4All | Completed | No outcome recorded |
| Phase 2 | NCT00948272 Comparator | Jul 2009 → Feb 2011 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00842530 Comparator | Feb 2009 → Sep 2013 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00652275 Comparator | May 2008 → Nov 2010 | Plasmodium falciparum malaria | African Malaria Network Trust | Unknown | No outcome recorded |
| Phase 2 | NCT00460525 Comparator | May 2007 → Jul 2009 | Plasmodium falciparum malaria | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 2 | NCT00380393 Comparator | Jan 2007 → Aug 2008 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00360230 Comparator | Aug 2006 → Aug 2007 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00197054 Comparator | Jul 2005 → Sep 2006 | Plasmodium falciparum malaria | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 2 | NCT00223990 Comparator | Apr 2005 → Apr 2006 | Plasmodium falciparum malaria | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 2 | NCT00703521 Comparator | Aug → Oct 2002 | rabies | Mahidol University | Completed | No outcome recorded |
| Phase 2 | NCT00031070 Background | ? → Dec 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07345208 Comparator | Dec 2025 → May 2027 expected | rabies | International Centre for Diarrhoeal Disease Research, Bangladesh | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT03264157 Background | Dec 2017 → Mar 2018 | — | Bio Products Laboratory | Completed | No outcome recorded |
| Phase 316 trials | ||||||
| Phase 3 | NCT07055295 Comparator | Mar → Dec 2026 expected | rabies | Sinovac Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07055893 Comparator | Mar 2026 → Jan 2027 expected | — | Sinovac Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05846568 Background | Oct 2022 → Sep 2023 | rabies | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04704830 Background | Apr 2021 → Mar 2023 overdue | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04594551 Comparator | Oct 2020 → Jun 2021 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT04644484 Background | Sep 2020 → Jun 2022 | Rhabdoviridae infectious disease, rabies | Synermore Biologics (Suzhou) Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04478084 Comparator | Aug 2020 → Mar 2022 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT04127786 Comparator | Oct 2019 → Mar 2020 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03965962 Comparator | Jul 2019 → Dec 2020 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03143218 Comparator | Apr 2017 → Mar 2020 | Plasmodium falciparum malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT02207816 Comparator | Sep 2014 → Jan 2017 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02177032 Comparator | Jun → Oct 2014 | rabies | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01466387 Comparator | Nov 2011 → Apr 2012 | Japanese encephalitis, meningococcal meningitis, rabies, typhoid fever +1 | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01339312 Comparator | Apr 2011 → Mar 2012 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00866619 Comparator | Mar 2009 → Mar 2011 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00345319 Comparator | Mar → May 2006 | rabies | Novartis Vaccines | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT03557008 Comparator | Jul 2018 → Jun 2022 | rabies | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT01365494 Comparator | Jul → Nov 2011 | rabies | Novartis Vaccines | Completed | No outcome recorded |
| Phase 4 | NCT00023504 Comparator | Jun 2002 → May 2017 | immunodeficiency disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 78 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rabies vaccine | “Rabies vaccine (RabAvert): RabAvert Rabies vaccine” NCT00349713 ↗30“purified chick-embryo cell-culture rabies vaccine” NCT07455318 ↗ |
| Known as | Abhayrab | “licensed rabies vaccine [Abhayrab]” PMID 38310910 ↗ Feb 2024 |
| Known as | Cell-culture rabies vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02207816 ↗ |
| Known as | ChengDa rabies vaccine | “Our findings demonstrate that the ChengDa rabies vaccine offers an alternative with a high degree of efficacy and yet limited side effects and ensures that the exposed patient...” PMID 21752947 ↗ Jul 2011 |
| Known as | Inactivated rabies virus vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00842530 ↗ |
| Known as | PCEC rabies vaccine | “12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection)” NCT02177032 ↗ |
| Known as | PCECV, Rabipur | “PCECV, Rabipur” NCT01107275 ↗ |
| Known as | Purified inactivated rabies vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04478084 ↗ |
| Known as | PVRV | “licensed purified Vero cell vaccine (PVRV; Verorab)” PMID 38478634 ↗ Jun 20241“Verorab® (PVRV; Purified Vero Cell Vaccine)” NCT02490956 ↗ |
| Known as | RabAvert | “The RABAVERT Vaccine is an inactivated, purified chick embryo cell vaccine (PCECV). It consists of lyophilized rabies virus (strain Flury LEP) that has been propagated in...” NCT04019444 ↗11“We conducted a first-in-human, phase 1, randomized, double-blind, dose-escalation trial comparing ChAd155-RG with a licensed inactivated vaccine (RabAvert) in healthy adults.” PMID 39418686 ↗ Oct 2024 “RabAvert®” NCT02040090 ↗ |
| Known as | Rabipur | “Male or female subjects between 5 and 17 months of age at the time of first vaccination received 3 doses of Rabipur vaccine administered intramuscularly in the left deltoid...” NCT00380393 ↗13“2 or 3 intradermal doses of 0.1 mL PCECV (Rabipur) were administered to 703 schoolchildren on days 0 and 28 or on days 0, 7, and 28.” PMID 17643772 ↗ Aug 2007 “Two group (Zagreb and Essen) will receive Rabipur vaccine IM according to either Zagreb or Essen schedules.” NCT01365494 ↗ “Subjects received Zagreb schedule (2-1-1) i.e. 4 vaccinations of Rabipur at days 1 , 8 and 22” NCT01680016 ↗ |
| Known as | Rabix-VC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04715867 ↗ |
| Known as | RVa | “Imovax (RVi) and Rabavert (RVa) rabies vaccines” NCT02956746 ↗ |
| Known as | Verorab | “A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab® when administered according to a...” PMID 24148575 ↗ Oct 201314“Verorab was licensed in 1985 for both pre- and post-exposure prophylaxis of rabies.” PMID 23510665 ↗ Mar 2013 “licensed purified Vero cell vaccine (PVRV; Verorab)” PMID 38478634 ↗ Jun 2024 “Group 2: Verorab + HRIG” NCT04594551 ↗ |
| Modality | Vaccine | “using Rabies vaccine immunization” NCT00023504 ↗ |
| Route | Intramuscular | “administered intramuscular deltoid” NCT00197054 ↗ |